Compare Mesoblast Limited (MESO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Toronto-Dominion Bank — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Toronto-Dominion Bank trades at $114.14 (market cap $186.61B). The key difference: Toronto-Dominion Bank is far larger — about 103.1× Mesoblast Limited's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Toronto-Dominion Bank for 84 Days on average.
| MESO | TD | |
|---|---|---|
Market Cap | $1.81B | $186.61B |
Volume | 240,620 | 4,056,663 |
Sector | Health | Financials |
52-Week High | $20.96 | $124.80 |
52-Week Low | $13.19 | $78.32 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | $1.89B | $559.39B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
TD stock trades at $114.04, down 3.5% today, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.98 versus $1.74 expected. The company announced a $10 billion share buyback program and is expanding its U.S. branch network. Revenue grew to $61.28 billion in 2025, with a net income margin of 24.88%.
The outlook is mixed: strong profitability and analyst buy ratings support upside, but bearish technicals and volatile cash flows pose risks. The stock's valuation appears reasonable with a P/E of 17.39. Key risks include execution of expansion plans and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
